Loading...
•
Sep 30, 2024
Tenaya Therapeutics Q3 2024 Earnings Report
Reported third quarter 2024 financial results and provided a corporate update.
Key Takeaways
Tenaya Therapeutics reported positive safety update and DSMB clearance to dose escalate to Cohort 2 in the MyPEAK-1 study. They remain on track to report early clinical data from the first three patients from Cohort 1 of this study in December. As of September 30, 2024, cash, cash equivalents and investments in marketable securities were $79.5 million.
Completed dosing of the first three patients at the 3E13 vg/kg dose (Cohort 1) in MyPEAK-1 clinical trial with no unexpected events or toxicities associated with study drug observed.
Implemented changes to the MyPEAK-1 protocol intended to support future development, including adding a baseline biopsy; expanding trial participant eligibility to include obstructive HCM patients and patients without implantable cardioverter defibrillators (ICDs).
TN-201 was granted rare pediatric disease designation by the U.S. Food and Drug Administration for the treatment of MYBPC3-associated HCM in individuals under the age of 18.
Entered into a $45 million credit facility with Silicon Valley Bank (SVB) in August 2024.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya estimates sufficient funds are available to support planned company operations into the second half of 2025.